Panchali Goswami

Panchali Goswami

Auto-generated profile, based on publicly available information

Panchali Goswami

GSK, Gunnels Wood Rd, Stevenage SG1 2NY, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
YKYeoun Jin Kim
Yeoun Jin Kim
SGSebastien Gallien
Sebastien Gallien
VKVictoria EL KHOURY
Victoria EL KHOURY
PGPanchali Goswami
Panchali Goswami
KSKatriina Sertamo
Katriina Sertamo
BDBruno Domon
Bruno Domon

Verified
Journal Article
Open access
PDF file
DVDaniele Veggi
Daniele Veggi
LILucia Dello Iacono
Lucia Dello Iacono
EMEnrico Malito
Enrico Malito
GMGiulietta Maruggi
Giulietta Maruggi
FGFabiola Giusti
Fabiola Giusti
MSMaria Scarselli
Maria Scarselli
The presentation of viral antigens on nanoparticles in multivalent arrays has emerged as a valuable technology for vaccines. On the nanoparticle surface, highly ordered, repetitive arrays of antigens can mimic their geometric arrangement on virion surfaces and elicit stronger humoral responses than soluble viral antigens. More recently, bacterial antigens have been presented on self-assembling protein nanoparticles and have elicited protective antibody and effective T-helper responses, further supporting the nanoparticle platform as a universal approach for stimulating potent immunogenicity. Here, we present the rational design, structural analysis, and immunogenicity of self-assembling ferritin nanoparticles displaying eight copies of the Neisseria meningitidis trimeric adhesin NadA. We engineered constructs consisting of two different NadA fragments, head only and head with stalk, that we fused to ferritin and expressed in Escherichia coli. Both fusion constructs self-assembled into the expected nanoparticles as determined by Cryo electron microscopy. In mice, the two nanoparticles elicited comparable NadA antibody levels that were 10- to 100-fold higher than those elicited by the corresponding NadA trimer subunits. Further, the NadAferritin nanoparticles potently induced complement-mediated serum bactericidal activity. These findings confirm the value of self-assembling nanoparticles for optimizing the immunogenicity of bacterial antigens and support the broad applicability of the approach to vaccine programs, especially for the presentation of trimeric antigens.